Loading...
Loading...
VRCA| Name | Value |
|---|---|
| Revenues | 3.8M |
| Cost of Revenue | 1.1M |
| Gross Profit | 2.7M |
| Operating Expense | 21.3M |
| Operating I/L | -18.6M |
| Other Income/Expense | -1.7M |
| Interest Income | 0.6M |
| Pretax | -20.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -20.3M |
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company that develops and commercializes treatments for skin diseases in the United States. The company's lead product candidate, VP-102, targets molluscum contagiosum, external genital warts, and common warts. Additionally, it is developing VP-103, a cantharidin-based product candidate for plantar warts. Verrica has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates in Japan. The company also has a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications.
